Corneal Regeneration
The cornea is the eye’s clear front window — the transparent layer that provides most of the eye’s focus. Unlike much of the body, it already regenerates a great deal of itself, but its deepest losses do not yet heal on their own. Corneal Regeneration is the effort to complete that repair: to protect the cornea’s own stem cells and nerves, rebuild its layers toward clarity rather than scar, and restore a clear, living surface from the cornea’s own biology — without creating new harm.
The goal is to safely regenerate the cornea — the eye’s clear front window — by awakening its own resident stem cells, nerves, and native repair, restoring clarity from the cornea’s own biology, with no new harm. The cornea already rebuilds much of itself; this page maps how research is learning to complete the repair it cannot yet finish — and names the honest stage of every step. Rebuilding a damaged cornea should be available to everyone who needs it. As we automate the global economy, we are driving the real cost of this regeneration toward zero — so that it becomes something freely given to everyone, at the point of use.
Vote Michael Floyd for President 2028.
The cornea is the eye’s transparent front layer and the source of most of its focusing power, and its clarity depends on constant self-renewal. Its surface is continuously rebuilt by its own limbal stem cells, its scaffold is maintained by resident repair cells, and it is the body’s most densely nerved tissue. But its innermost layer barely divides in adults, and deep wounds can heal as scar instead of clear tissue. The hopeful science: the cornea already regenerates much of itself, and research is learning to safely complete the repair it cannot yet finish.
Regenerating the cornea would change what corneal blindness means. Today, chemical burns, infections, injuries, and inner-layer failure cloud the cornea and remain a leading cause of blindness worldwide — and the standard answer, donor tissue, is scarce and not always lasting. If the cornea could rebuild a clear surface, nerves, and scaffold from a person’s own cells, far more sight could be restored from the cornea’s own biology rather than from a limited supply of donor corneas.
Corneal disease and injury are among the most treatable causes of blindness — and increasingly, the cornea can be restored from a person’s own cells. Completing that capability would turn many corneal conditions from a wait for scarce donor tissue into recovery the body can grow for itself.
No person should lose sight to a clouded cornea when the cornea already renews its own surface every day and carries the stem cells to rebuild it. Corneal Regeneration is built on a simple belief: a clear, living window restored from the body’s own cells — safely, with as little intervention as possible, and without trading one harm for another.
Build the capability to safely regenerate the cornea: protect its resident stem cells and the avascular clarity they maintain, sustain its daily surface renewal, regrow its nerves, rebuild its scaffold toward clear tissue instead of scar, restore a lost surface from the body’s own cells, and — at the hardest frontier — safely reawaken the inner layer’s latent repair, all from the cornea’s own biology and building on lifelong visual resilience. Where the surface’s own stem cells are gone, grafts grown from the patient’s own remaining cells can rebuild what was lost.
One place for the whole picture: how each regeneration capability works, the breakthrough that proves it is real, and the research and institutions behind it. We name the honest stage of every step, and never present laboratory or early-trial results as finished, routine care.
These capabilities are not separate, competing cures — they are stages of one connected path, each handing off to the next, from protecting the cornea’s stem cells to restored clarity:
The path above is the journey. The capabilities below are the science that makes it possible — the proven breakthroughs, and the people who achieved them. Some stages draw on several capabilities; some capabilities serve more than one stage.
Protect the cornea’s stem cells and clarity Demonstrated · clinical
Demonstrated components (today): the cornea’s surface is renewed for life by limbal stem cells living in a niche at the cornea’s rim, and those same cells help keep the cornea transparent and free of blood vessels. This own-cell biology is real and well-characterized: protect that population and its avascular clarity, and the cornea keeps its proven ability to repair itself; lose them, and the window clouds.
The capability being built toward: when fully built, the aim is to reliably preserve both the stem-cell reservoir and the clear, vessel-free state before any deeper repair — the corneal side of vision preservation, safeguarding the cells and clarity that all regeneration depends on. What is real today is the known biology of the limbal niche and avascular cornea; the frontier is consistently protecting them across age, injury, and disease so the cornea never loses its capacity to heal.
Limbal epithelial stem cells and their niche, the limbal barrier that keeps blood vessels and conjunctiva off the cornea, and the cornea’s actively maintained avascular, immune-privileged transparency — the resident biology that must be preserved for repair to be possible.
The cornea keeps its own master stem cell. Graziella Pellegrini and Michele De Luca at the University of Modena and Reggio Emilia showed that a single limbal stem-cell clone — a “holoclone” — can regenerate and sustain the entire corneal surface, identifying the exact cell whose survival every corneal repair depends on.
A living barrier that keeps the window clear. Scheffer Tseng’s work at the Ocular Surface Center and Bascom Palmer Eye Institute defined limbal stem-cell deficiency and showed the limbus is the barrier that keeps blood vessels and conjunctiva off the cornea — when it fails the cornea vascularizes and clouds, so protecting it preserves transparency.
The cornea’s vessel-free privilege, explained. Reza Dana’s group at the Schepens Eye Research Institute and Harvard Medical School showed the cornea actively defends its avascular, immune-privileged state — for example by producing soluble decoy receptors that keep blood vessels from invading — the biology that maintains a clear window.
Research & institutions: Graziella Pellegrini and Michele De Luca at the University of Modena and Reggio Emilia, Scheffer Tseng at the Ocular Surface Center and Bascom Palmer Eye Institute, Reza Dana at the Schepens Eye Research Institute and Harvard Medical School, Friedrich Kruse at the University of Erlangen, Ula Jurkunas at Mass Eye and Ear, the foundational limbal-stem-cell work of Tung-Tien Sun and Robert Lavker, the LV Prasad Eye Institute, the Singapore Eye Research Institute, Moorfields Eye Hospital and University College London, the National Eye Institute, the Department of Defense Vision Research Program (CDMRP), and the broader limbal-niche and ocular-surface field.
Reach the cornea without harm Demonstrated · clinical
Demonstrated components (today): because the cornea is the eye’s accessible outer surface, harm-free delivery is further along here than anywhere else in the eye. Eye drops and topical biologics already reach the surface and its nerves, and grafts of the body’s own cells are placed directly on the eye’s surface without cutting into the eye.
The capability being built toward: when fully built, the aim is to deliver every regenerative or protective signal — and the cornea’s own cells — to the right layer (surface, nerves, stroma, inner endothelium) through fully noninvasive routes, without injections into the eye or new injury. What is real today is topical and surface-graft delivery to the outer cornea; the frontier is reaching deeper layers like the endothelium just as gently. The biology is only half the story — routing each signal or cell to its target layer safely is the other half.
Named noninvasive routes for the cornea: eye drops and topical biologics (nerve-growth-factor drops, ROCK-inhibitor drops) that reach the surface, the nerves, and even the inner endothelium; own-cell grafts (cultivated limbal epithelial transplant, simple limbal epithelial transplantation) placed on the accessible ocular surface; and drop-based delivery of survival and regenerative signals. Because the cornea is the eye’s outer surface, much of its regenerative cargo can be delivered as a drop — the reason corneal delivery is further along than retina, optic nerve, or cochlea.
Regenerative biologics delivered as drops, in the clinic. Cenegermin (recombinant human NGF; Alessandro Lambiase and colleagues, FDA-approved 2018) heals the ocular surface and regrows corneal nerves with no needle and no operation. ROCK-inhibitor eye drops (Shigeru Kinoshita and colleagues at Kyoto Prefectural University) are restoring the corneal endothelium by drop in clinical work — reaching the eye’s innermost corneal layer noninvasively.
The body’s own cells, placed on the surface. Cultivated limbal epithelial transplant (CALEC; Ula Jurkunas at Mass Eye and Ear) and Holoclar (Graziella Pellegrini and Michele De Luca, EMA-approved 2015) restore the surface from a person’s own limbal stem cells, placed directly on the accessible ocular surface. Deeper grafts and cell processing remain an honest current boundary the drop-based routes keep narrowing.
Research & institutions: Alessandro Lambiase at Sapienza University of Rome, Shigeru Kinoshita at Kyoto Prefectural University of Medicine, Ula Jurkunas at Mass Eye and Ear and Harvard Medical School, Graziella Pellegrini and Michele De Luca at the University of Modena, and the broader ocular-surface and drug-delivery field.
Sustain the cornea’s daily surface renewal Demonstrated · clinical
Demonstrated components (today): the cornea is already a regenerating tissue. Every day its limbal stem cells send a stream of new cells inward to replace the surface, and when the surface is scratched, the cells migrate to cover the wound, then divide to rebuild the layers. This daily, proven self-renewal is observable now — it is the cornea’s most clinically real regenerative behavior.
The capability being built toward: when fully built, the aim is to read exactly how and where the cornea repairs itself, protect those systems as they weaken with age, and amplify them so more of the surface can benefit and deeper regeneration has a foundation to build on. What is real today is the cornea’s spontaneous daily renewal and wound closure; the direction is strengthening and widening that proven capacity into a platform for more demanding repair.
Limbal-stem-cell-driven epithelial renewal, centripetal migration of cells from the limbus to the central cornea, migrate-then-divide wound healing, and the molecular markers and niche signals that identify and maintain the repairing cells.
The cornea’s renewal, watched cell by cell in living tissue. Nick Di Girolamo’s lab at the University of New South Wales used multicolor genetic tagging and live imaging in mice to watch individual limbal stem cells stream inward and rebuild the corneal surface in real time (Di Girolamo et al., Stem Cells, 2015) — directly revealing how the cornea continuously renews itself.
The marker that tells the repair cells apart. Bruce Ksander, Markus Frank, and Natasha Frank at the Schepens Eye Research Institute, Harvard Medical School, and the Boston VA identified ABCB5 as a marker of limbal stem cells and showed those cells are required to regenerate the cornea (Ksander et al., Nature, 2014) — the knowledge needed to find, protect, and amplify the right cells.
The rule that maps how the surface maintains itself. Richard Thoft’s classic “X, Y, Z” hypothesis established that the cornea balances cells lost from the surface against new cells supplied by the limbus — the framework, since confirmed by live imaging, that explains how the cornea keeps its surface whole.
Research & institutions: Nick Di Girolamo at the University of New South Wales, Bruce Ksander and Markus Frank at the Schepens Eye Research Institute and Harvard Medical School, the foundational work of Richard Thoft, the foundational limbal-stem-cell work of Tung-Tien Sun and Robert Lavker, Panteleimon Rompolas at the University of Pennsylvania, Graziella Pellegrini and Michele De Luca at the University of Modena and Reggio Emilia, Friedrich Kruse at the University of Erlangen, the Singapore Eye Research Institute, Moorfields Eye Hospital and University College London, the National Eye Institute, the Department of Defense Vision Research Program (CDMRP), and the broader corneal-epithelial and limbal-stem-cell field.
Regrow the cornea’s own nerves Clinical · frontier
Demonstrated components (today): the cornea is the most densely nerved tissue in the body; its own nerves keep the surface sensate, trigger blinking and tears, and signal the surface to heal. When injury or disease severs them — a condition called neurotrophic keratitis — the cornea goes numb and stops healing. A regenerative protein given simply as a drop already restores part of this reinnervation in patients today.
The capability being built toward: when fully built, the aim is to regrow the cornea’s own nerves completely and quickly, so the surface can feel and repair itself again and the cornea becomes self-maintaining. What is real today is a clinically used drop that drives partial nerve regrowth; the frontier — shared with nerve regeneration — is speeding and completing reinnervation so sensation and healing fully return.
Sub-basal corneal nerve regeneration, nerve growth factor and other neurotrophic signaling, and the reinnervation that restores corneal sensation and the surface’s ability to heal — partly clinical today, with full, fast recovery still a frontier.
Regrowing the cornea’s nerves with a protein it already uses. Alessandro Lambiase and Stefano Bonini (Sapienza and Campus Bio-Medico University of Rome) developed recombinant human nerve growth factor eye drops — cenegermin, FDA-approved in 2018 — and showed in controlled trials that they heal neurotrophic ulcers and regrow corneal nerves, a regenerative biologic delivered noninvasively as a drop.
Seeing the nerves come back. Pedram Hamrah’s research at Tufts University used in-vivo confocal microscopy to image the cornea’s sub-basal nerve plexus and track its regeneration after injury — making nerve recovery directly measurable and showing the cornea’s own nerves can return.
The honest limit, and the frontier. After injury the cornea’s nerves regrow from the surrounding supply, but in people this reinnervation is slow and often incomplete — so restoring full, fast recovery, the goal Lambiase, Bonini, and Hamrah’s clinical work points toward, remains an active frontier shared with peripheral-nerve regeneration.
Research & institutions: Alessandro Lambiase and Stefano Bonini at the universities of Rome, Pedram Hamrah at Tufts University, Reza Dana at the Schepens Eye Research Institute and Harvard Medical School, Mark Rosenblatt at the University of Illinois Chicago, Carol Marfurt at the Indiana University School of Medicine, the Bascom Palmer Eye Institute, the Singapore Eye Research Institute, Dompé, the National Eye Institute, the Department of Defense Vision Research Program (CDMRP), and the broader corneal-nerve and neurotrophic-keratitis field.
Rebuild the stroma toward clarity, not scar Clinical · frontier
Demonstrated components (today): most of the cornea’s thickness is the stroma, a precisely arranged collagen scaffold whose order is what makes the cornea clear. After injury the cornea’s own resident cells, keratocytes, rebuild that scaffold; when the repair resolves correctly the cornea heals clear — a real, observed outcome — but when it goes wrong the result is scar and haze.
The capability being built toward: when fully built, the aim is to steer stromal repair reliably toward transparent tissue rather than scar, completing the cornea’s own rebuild even for deeper wounds and keeping healing on the regenerative path. What is real today is that keratocytes already regenerate clear stroma in favorable cases; the frontier is controlling that outcome for serious injury — the corneal version of turning scar into true regeneration.
Keratocyte-driven repair of the collagen stroma and basement membrane, control of the myofibroblasts that cause haze, and corneal stromal stem cells that regenerate clear native tissue — clinical for milder injury, with scar-free repair of deep wounds still a frontier.
Why some corneas heal clear and others scar. Steven Wilson’s lab at the Cleveland Clinic showed that haze comes from myofibroblasts that persist when the cornea’s basement membrane fails to regenerate — and that once the basement membrane is restored, those scarring cells disappear and clarity returns, defining how to steer healing toward transparency.
Clear scaffold grown from the cornea’s own stem cells. James and Martha Funderburgh at the University of Pittsburgh showed that corneal stromal stem cells regenerate native, transparent stromal tissue and suppress scarring — in models even remodeling existing scar toward clear tissue — rebuilding a clear scaffold rather than an opaque one.
Restoring the scaffold from a person’s own cells. Building on this, stromal-stem-cell and own-cell approaches (advanced by groups including the LV Prasad Eye Institute) aim to repair the stroma with the patient’s own regenerative cells, a route toward clear corneal tissue without donor grafts.
Research & institutions: Steven Wilson at the Cleveland Clinic, James and Martha Funderburgh at the University of Pittsburgh, the LV Prasad Eye Institute, May Griffith’s corneal-regeneration research, the Schepens Eye Research Institute and Harvard Medical School, the Singapore Eye Research Institute, the University of Pittsburgh McGowan Institute for Regenerative Medicine, the Cleveland Clinic Cole Eye Institute, the University of Auckland corneal-bioengineering research, the National Eye Institute, the Department of Defense Vision Research Program (CDMRP), and the broader corneal-stroma and scar-free-healing field.
Restore the surface from the body’s own cells Approved in Europe · clinical
Demonstrated components (today): when the surface’s own limbal stem cells have been destroyed — by a chemical burn, infection, or disease — the cornea can no longer renew itself and it clouds. Restoration from the patient’s own remaining cells is clinically real: a small biopsy of healthy limbal tissue is expanded into a living graft and returned to the eye, restoring a clear, self-renewing surface. This is an approved therapy in Europe (Holoclar) — among the most clinically proven own-cell regenerative treatments anywhere in the body.
The capability being built toward: when fully built, the aim is to extend this own-cell restoration to more patients and harder cases, drawing on the body’s own biology rather than scarce donor corneas. What is real today is an approved, working autologous graft for surface renewal; the direction is broadening that foundation of lifelong visual resilience.
Cultured limbal stem-cell grafts and simple limbal epithelial transplantation grown from a patient’s own remaining healthy tissue, restoring a clear, self-renewing corneal surface in limbal stem-cell deficiency — clinically proven and, in Europe, approved.
Sight restored from a patient’s own stem cells. Graziella Pellegrini and Michele De Luca at the University of Modena and Reggio Emilia restored sight to patients blinded by chemical burns using the patients’ own cultured limbal stem cells — reported in 112 patients in the New England Journal of Medicine (2010) and approved in Europe as Holoclar in 2015, the first stem-cell medicine approved in the Western world.
Repairing “irreversible” corneal damage — 2025. Ula Jurkunas and the cornea team at Mass Eye and Ear and Harvard Medical School, with Dana-Farber and Boston Children’s Hospital, ran the NEI-funded CALEC trial (cultivated autologous limbal epithelial cells): in 14 patients followed 18 months, over 90% (in this first small US trial) achieved complete or partial restoration of the corneal surface — the first such stem-cell therapy trialed in the United States (Nature Communications, 2025).
A simpler own-cell route. Virender Sangwan at the LV Prasad Eye Institute developed simple limbal epithelial transplantation (SLET), restoring the surface from a small piece of the patient’s own healthy limbus in a single step — making own-cell surface restoration far more widely accessible.
Research & institutions: Graziella Pellegrini and Michele De Luca at the University of Modena and Reggio Emilia and Holostem Terapie Avanzate, Ula Jurkunas and the cornea service at Mass Eye and Ear and Harvard Medical School (the CALEC trial), Virender Sangwan at the LV Prasad Eye Institute, Sajjad Ahmad at Moorfields Eye Hospital and University College London, Ali Djalilian at the University of Illinois Chicago, Friedrich Kruse at the University of Erlangen, Bascom Palmer Eye Institute, the Centre for Eye Research Australia, the Singapore Eye Research Institute, the National Eye Institute, the Department of Defense Vision Research Program (CDMRP), and the broader autologous limbal stem-cell and ocular-surface restoration field.
Reawaken the inner endothelium — the honest frontier Frontier · clinical trials
Demonstrated components (today): the cornea’s innermost layer, the endothelium, pumps water out of the cornea to keep it clear, but in adult humans it barely divides — so its losses are the hardest to replace and a leading reason corneas cloud with age. These cells do retain a latent ability to divide, held in a resting state, and early human results — including injecting cultured endothelial cells — already exist.
The capability being built toward: when fully built, the aim is to safely release that dormant capacity, or rebuild the inner layer from the body’s own cultured cells, so the cornea clears itself without a full transplant. This is the cornea’s hardest, most honest frontier: what is real today is encouraging but early human evidence; the direction is turning those first results into a dependable way to reawaken the inner layer.
Endothelial cell-cycle re-entry, cultured corneal endothelial cells delivered with a ROCK-pathway signal, and migration-based self-repair of the inner layer — releasing a latent capacity, demonstrated in early clinical trials and laboratory work.
Injecting the cornea’s own inner cells back to clarity. Shigeru Kinoshita and Naoki Okumura at Kyoto Prefectural University of Medicine restored corneal clarity by injecting lab-expanded human corneal endothelial cells together with a ROCK-pathway signal that helps them attach and work — patients regained clear vision without a full corneal transplant (New England Journal of Medicine, 2018), early proof the inner layer can be rebuilt from cultured cells.
Letting the eye heal its own inner layer. Kathryn Colby, then at Mass Eye and Ear, pioneered “Descemet stripping only,” in which simply removing the damaged central inner layer lets a patient’s own endothelial cells migrate in and clear the cornea — sometimes aided by ROCK-inhibitor drops — restoring clarity from the cornea’s own cells.
Proof the capacity is only suppressed. Nancy Joyce’s research at the Schepens Eye Research Institute showed that adult corneal endothelial cells retain the capacity to divide but are held in arrest — evidence that the inner layer’s repair is silenced, not lost, and therefore re-openable.
Research & institutions: Shigeru Kinoshita and Naoki Okumura at Kyoto Prefectural University of Medicine and Doshisha University, Kathryn Colby at NYU and formerly Mass Eye and Ear, the late Nancy Joyce at the Schepens Eye Research Institute, Jodhbir Mehta at the Singapore Eye Research Institute, Ula Jurkunas at Mass Eye and Ear, Kohji Nishida at Osaka University, Albert Jun at the Johns Hopkins Wilmer Eye Institute, Aurion Biotech, the National Eye Institute, the Department of Defense Vision Research Program (CDMRP), and the broader corneal-endothelial regeneration field.
Restore clarity, not just cells Clinical goal
Demonstrated components (today): the true measure of corneal regeneration is not new cells but restored clarity and sight — a transparent window and an eye that focuses again. Individually, the pieces are real and even clinical: renewed surface, regrowing nerves, clearer scaffold, and early endothelial repair each already exist, drawn from the cornea’s own biology.
The capability being built toward: when fully built, the aim is for these to come together so light passes cleanly to the retina and genuine functional recovery follows — from the cornea’s own biology and from as little intervention as possible. What is real today is meaningful restoration in individual layers; the frontier is unifying them into whole-cornea clarity, the link to vision restoration and the complete vision capability.
Integration of surface, nerve, stromal, and endothelial repair into restored corneal transparency and visual acuity — the combined outcome that turns regenerated cells into usable, clear sight.
A clear surface, measured as restored sight. The Holoclar and CALEC results judged success not by cells alone but by restored corneal clarity and vision in patients — Pellegrini, De Luca, and Jurkunas’s trials reported regained visual acuity and a stable, clear surface, the real-world proof that own-cell regeneration restores sight.
A public commitment to corneal repair. The National Eye Institute funded the first US stem-cell therapy for the cornea (the CALEC trial), making restored corneal clarity an explicit federal research goal rather than a hope.
Restoring vision after injury. The U.S. Department of Defense Vision Research Program (CDMRP) funds repair of corneal and ocular-surface injury — advancing the same end goal of usable, clear sight recovered from the body’s own biology.
Research & institutions: Graziella Pellegrini and Michele De Luca at the University of Modena and Reggio Emilia, Ula Jurkunas at Mass Eye and Ear and Harvard Medical School, the National Eye Institute, the Department of Defense Vision Research Program (CDMRP), the LV Prasad Eye Institute, the Singapore Eye Research Institute, Moorfields Eye Hospital and University College London, Bascom Palmer Eye Institute, the Cleveland Clinic Cole Eye Institute, the Wilmer Eye Institute at Johns Hopkins, the Foundation Fighting Blindness, and the broader corneal-restoration and vision-recovery field.
Corneal Regeneration is not a single invention. It is the integration of biology, research programs, institutions, and public investment into one effort to restore the eye’s clear window from the body’s own cells.
Making this real means sustaining the public research that maps the cornea’s own repair, protecting the stem cells and clarity people still have, advancing surface, nerve, stromal, and inner-layer regeneration together, proving safety and durability in people, and ensuring own-cell restoration reaches everyone — not only those who can reach a handful of specialist centers.
The goal is simple: turn corneal blindness from a wait for scarce donor tissue into recovery the body can grow for itself — safely, from the cornea’s own cells, and without creating new harm.
Vote Michael Floyd for President 2028.
The honest boundary: the cornea regenerates much of itself, but its deepest repairs are not yet finished science. Restoring a lost surface from a person’s own cells is clinically real and approved in Europe, yet it still involves a graft procedure; regrowing nerves is partial; rebuilding the stroma without scar and reawakening the inner endothelium are early-stage. Today’s most advanced steps can involve surgery, cell processing, or donor tissue. These are important and often clinically real, but under Michael Floyd’s Healthy standard the aim is to keep moving toward versions that are noninvasive, durable, safe, and free of treatment-related harm, built on the cornea’s own cells. So the real challenges are completing scar-free repair, speeding reinnervation, safely reawakening the inner layer, and making own-cell restoration simple enough for everyone — and we name the honest stage of every step.
Picture the day the cornea can fully repair itself. A clouded cornea no longer means a wait on a donor list or a lifetime of dimmed sight — it means a plan to rebuild a clear, living window from the eye’s own cells, surface and nerves and scaffold and inner layer alike.
Families stop watching a loved one’s world turn hazy and gray. The clear view of a face, a page, a road is kept or brought back, because the cornea that clouded can be made clear again from a person’s own biology.
Society regains what corneal blindness takes — people kept reading, working, and living independently, and the worldwide shortage of donor corneas stops being the limit on who can see, because the cornea can be restored from the body’s own cells.
Eye care shifts from replacing the cornea with scarce donor tissue to regenerating it — this is Michael Floyd’s Healthy standard applied to the cornea, the same standard that works to prevent, regenerate, restore, and optimize health across the entire body, all by the body’s own repair. Care is as noninvasive as the science allows, and the aim is always the same: the cornea’s own cells, doing the cornea’s own work, without new harm.
And America becomes a country that decides corneal blindness should not be permanent — and helps turn a worldwide scientific effort into recovery its people can actually receive, by the cornea’s own biology and without new harm.
Help Build Corneal Regeneration
No person should lose sight to a clouded cornea when the cornea already renews its own surface every day and carries the stem cells to rebuild it. No one should wait on scarce donor tissue when their own cells can restore a clear window.
This future will not build itself.
It requires researchers, engineers, healthcare professionals, patients, families, supporters, volunteers, organizers, donors, and citizens working together to make regenerative, restoration-first healthcare available to everyone. If you believe a clear cornea should be recoverable from the body’s own cells, join the movement helping build that future.
Help build Free Safe Healthy.